Adjuvant Atezolizumab Should Be Administered to All Patients With Programmed Death-Ligand 1 Expressing Surgically Resected Stage II to III NSCLC After Chemotherapy: In Favor

J Thorac Oncol. 2023 Mar;18(3):265-267. doi: 10.1016/j.jtho.2022.12.004.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / surgery
  • Chemotherapy, Adjuvant
  • Humans
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / surgery

Substances

  • atezolizumab
  • CD274 protein, human
  • Antibodies, Monoclonal, Humanized